← Back to patent-cliff list
酒石酸溴莫尼定/马来酸噻吗洛尔
Tier C — Watch / tradeBrimonidine Tartrate/Timolol Maleate
艾尔建
Originator
2007
First approval
-
Expiry (public)
$0.53B ▲
Peak sales
化学药
Type
Targets：β-adrenoceptors、ADRA2
Brand：Combigan
Indications (approved)：高眼压、青光眼
Regional status
US
批准上市
2007-10-30
EU
-
China
批准上市
2014-12-09
Japan
批准上市
2019-12-01
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Brimonidine Tartrate/Timolol Maleate?
Approved indications include: 高眼压, 青光眼.
When does the Brimonidine Tartrate/Timolol Maleate patent expire?
No public expiry year is available for Brimonidine Tartrate/Timolol Maleate yet; this page updates once verified.
How do I get a quote for Brimonidine Tartrate/Timolol Maleate intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-24